NCCN Clinical Practice Guidelines in Oncology® for Myelodysplastic Syndromes Updated
The NCCN Clinical Practice Guidelines in Oncology® for Myelodysplastic Syndromes (MDS) have been updated and published by the National Comprehensive Cancer Network. The current version is 1.2010. In the updated version, the category of evidence and consensus for recommending azacytidine for the treatment of higher risk MDS patients (IPSS risk category INTERMEDIATE-2 and High) is now Category 1. Previously, this recommendation was Category 2A. Updates also include the addition of azacytidine, decitabine, or participation in a clinical trial as recommended options for higher risk patients who relapse following allogeneic hemopoietic stem cell transplant.
NCCN Clinical Practice Guidelines in Oncology® for Cancer- and Chemotherapy- Induced Anemia Updated
The current version of the NCCN Guidelines for Cancer- and Chemotherapy- Induced Anemia is now v.1.2010. Updates included reference to new meta-analyses that further confirmed increased mortality risks associated with ESAs and treatment recommendations for no iron deficiency in asymptomatic patients with risk factors for developing anemia.